

**Charles University, Faculty of Medicine in Hradec Králové**

**Dean's Directive No. 12/2025**

Ref. No.: UKLFHK/588965/2025

Title: **Ensuring the Possibility to Continue Studies in an Identical or Similar Programme of Study**

Force and effect: on the date of execution by the Dean

*The following Dean's directive has been adopted to implement Rector's Directive No. 9/2024, Details on Ensuring the Possibility to Continue Studies in an Identical or Similar Programme of Study in the Case of Termination of Accreditation and the Right to Offer a Programme of Study under Institutional Accreditation:*

Article 1

**Subject-matter**

1. The present directive regulates further details and organisational matters related to ensuring the possibility to continue studies in an identical or similar programme of study at the Faculty if the accreditation of a doctoral programme of study is terminated:
  - Anatomy, Histology and Embryology, study programme code: P0912D350077,
  - Medical Biology, study programme code: P0912D350041,
  - Physiology and Pathophysiology, study programme code: P0912D350063,
  - Medical Biophysics, study programme code: P0912D350045,
  - Medical Pharmacology, study programme code: P0912D350052,
  - Medical Chemistry and Biochemistry, study programme code: P0912D350058,
  - Medical Chemistry and Biochemistry, study programme code: P0912D350059.
2. The programmes of study are implemented on the basis of the respective curricula which provide further details on the programmes.
3. Completion-of-study curricula are designed for students to complete their studies in the newly accredited programmes of study without major changes.

Article 2

**Successor programmes of study**

1. In Resolution of 25 June 2025, Ref. No. UKRUK/426544/2025-1, the Internal Evaluation Board of Charles University decided that the successor programme of study for the Anatomy, Histology and Embryology (study programme code: P0912D350077), Medical Biology (study programme code: P0912D350041), and Physiology and Pathophysiology (study programme code: P0912D350063) doctoral programmes, the accreditation of which has been terminated, is the Biomedical Sciences (study programme code: P0912D350012) programme of study.
2. In Resolution of 25 June 2025, Ref. No. UKRUK/426544/2025-1, the Internal Evaluation Board of Charles University decided that the successor programme of study for the

Medical Biophysics (study programme code: P0912D350045) doctoral programme, the accreditation of which has been terminated, is the Applied Physics and Mathematics in Medicine and Pharmacy (study programme code: P0988D350010) programme of study.

3. In Resolution of 25 June 2025, Ref. No. UKRUK/426544/2025-1, the Internal Evaluation Board of Charles University decided that the successor programme of study for the Medical Pharmacology (study programme code: P0912D350052) doctoral programme, the accreditation of which has been terminated, is the Pharmacology and Toxicology (study programme code: P0916D080026) programme of study.
4. In Resolution of 25 June 2025, Ref. No. UKRUK/426544/2025-1, the Internal Evaluation Board of Charles University decided that the successor programme of study for the Medical Chemistry and Biochemistry (study programme code: P0912D350058) doctoral programme, the accreditation of which is terminated, is the Xenobiochemistry and Pathobiochemistry (study programme code: P0916D080023) programme of study.
5. In Resolution of 25 June 2025, Ref. No. UKRUK/426544/2025-1, the Internal Evaluation Board of Charles University decided that the successor programme of study for Medical Chemistry and Biochemistry (study programme code: P0912D350059) doctoral programme, the accreditation of which has been terminated, is the Xenobiochemistry and Pathobiochemistry (study programme code: P0916D080024) programme of study.

### Article 3

#### **Date of assignment to a completion-of-study curriculum**

1. Students enrolled in the 2024/2025 academic year in the Anatomy, Histology and Embryology (study programme code: P0912D350077) doctoral programme, the accreditation of which has been terminated, including those who interrupted their study, will be assigned to the successor programme of study Biomedical Sciences (study programme code: P0912D350012) as of 23 September 2025.
2. Students enrolled in the 2025/2026 academic year in the Medical Biology (study programme code: P0912D350041) and Physiology and Pathophysiology (study programme code: P0912D350063) doctoral programmes, the accreditation of which has been terminated, including those who interrupted their study, will be assigned to the successor programme of study Biomedical Sciences (study programme code: P0912D350012) as of 1 October 2025.
3. Students enrolled in the 2025/2026 academic year in the Medical Biophysics (study programme code: P0912D350045) doctoral programme, the accreditation of which has been terminated, including those who interrupted their study, will be assigned to the successor programme of study Applied Physics and Mathematics in Medicine and Pharmacy (study programme code: P0988D350010) as of 1 October 2025.

4. Students enrolled in the 2025/2026 academic year in the Medical Pharmacology (study programme code: P0912D350052) doctoral programme, the accreditation of which has been terminated, including those who interrupted their study, will be assigned to the successor programme of study Pharmacology and Toxicology (study programme code: P0916D080026) as of 1 October 2025.
5. Students enrolled in the 2025/2026 academic year in the Medical Chemistry and Biochemistry (study programme code: P0912D350058) doctoral programme, the accreditation of which has been terminated, including those who interrupted their study, will be assigned to the successor programme of study Xenobiochemistry and Pathobiochemistry (study programme code: P0916D080023) as of 1 October 2025.
6. Students enrolled in the 2025/2026 academic year in the Medical Chemistry and Biochemistry (study programme code: P0912D350059) doctoral programme, the accreditation of which has been terminated, including those who interrupted their study, will be assigned to the successor programme of study Xenobiochemistry and Pathobiochemistry (study programme code: P0916D080024) as of 1 October 2025.

#### Article 4

#### **Final provisions**

1. In matters not regulated hereunder, the continuation of study is governed by Rector's Directive No. 9/2024, Details on Ensuring the Possibility to Continue Studies in an Identical or Similar Programme of Study in the Case of Termination of Accreditation and the Right to Offer a Programme of Study under Institutional Accreditation.
2. The present Directive comes into force and effect on the date of execution by the Dean.
3. The draft directive was discussed by the Dean's Board on 18 September 2025.

Hradec Králové, 30 September 2025

prof. MUDr. Jiří Mand'ák, Ph.D.  
Dean